Weston Brain Institute - Early Phase Clinical Trials: Canada

The Weston Brain Institute is pleased to launch the Early Phase Clinical Trials: Canada program.

This opportunity provides funding for clinical trials and clinical trial sub-studies that accelerate the development of therapeutics for neurodegenerative diseases of aging

The Early Phase Clinical Trials program was created to provide significant support for clinical trials and/or clinical trial sub-studies that have excellent preliminary data.

The Institute has updated which tools are in scope. Please read What We Fund before applying to ensure your project is in scope

The Early Phase Clinical Trials: Canada program will be run on a rolling basis
 

Institute definition of neurodegenerative diseases of aging:

  • Alzheimer’s disease
  • Dementia with Lewy bodies
  • Frontotemporal dementia
  • Multiple system atrophy
  • Parkinson’s disease
  • Progressive supranuclear palsy
  • Vascular contributions to the above diseases
  • Prodromes to the above diseases

For more information, please visit our website.

 

Application Procedures

There are two stages to the application process:

  • Letters of Intent (LOI)
  • Proposal

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited.

Applicants can expect to receive the outcome of their LOI application within ~2 months of submission.

Eligibility Summary

Principal applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. 
Project must be a clinical trial and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging, and must involve the development of a therapeutic, and/or a tool.

Deadline

Sunday, 31 December 2017

Annual Value

$1,500,000 over 4 years